Sr. Director/Executive Director of Drug Safety & Pharmacovigilance
Skyhawk Therapeutics seeks a Sr. Director/Executive Director of Pharmacovigilance & Drug Safety to support product safety and compliance. The successful candidate will report to the SVP of Clinical Development and be responsible for managing drug safety data to support signal detection and risk/benefit profile evaluation, author safety documents, perform QC of safety documents, organize cross-functional Safety Management Team meetings. The successful candidate will oversee the ICSR data quality from safety vendors and ensure compliance with all applicable US and foreign legal and regulatory requirements to ensure compliance with global drug safety regulations while working in a highly collaborative work environment with a multi-disciplinary and diverse team, focusing on multiple programs in parallel.
Responsibilities:
Collaborate, and oversee the work of CROs directly involved in ICSR management, aggregate & periodic reporting, and business partner reporting
Support signal detection and risk management activities
Support Development activities as a member of CTT
Other activities
Education/Skills/Experience Requirements:
Skyhawk Therapeutics is committed to pay transparency and equitable compensation practices. The base salary range for the Sr. Director/Executive Director of Drug Safety & Pharmacovigilance is $300,000-4450,000 annually. This range reflects the minimum and maximum target for such position. Skyhawk Therapeutics will assess the appropriate level for a qualified candidate based on job-related skills, professional experience, and relevant education or training.
About Skyhawk
Skyhawk is committed to discovering, developing and commercializing small molecule therapeutics that modify RNA expression. We use our novel SkySTAR® platform (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) to develop drug candidates directed toward targets for some of the world’s most intractable diseases including neurological conditions, cancer, and traditionally “undruggable” targets.